

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/395, G01N 33/53, 33/533, 33/536	A1	(11) International Publication Number: WO 94/25022 (43) International Publication Date: 10 November 1994 (10.11.94)
(21) International Application Number: PCT/US94/04434 (22) International Filing Date: 22 April 1994 (22.04.94) (30) Priority Data: 08/053,030 23 April 1993 (23.04.93) US 08/224,205 14 April 1994 (14.04.94) US (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: GONZALEZ, Eduardo; 726 North Walnut Avenue, 2E, Waukegan, IL 60085 (US). RUSSELL, John, C.; 3925 W. Iona Terrace, Greenfield, WI 53221 (US). MOLNAR- KIMBER, Katherine, L.; 222 Harrison Avenue, Glenside, PA 19038 (US). (74) Agents: GORMAN, Edward, H., Jr. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US).		(81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: RAPAMYCIN CONJUGATES AND ANTIBODIES (57) Abstract Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin or a derivative thereof, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides monoclonal antibodies specific for rapamycin or a ring opened derivative of rapamycin.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LV	Latvia	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MD	Republic of Moldova	TJ	Tajikistan
DE	Germany	MG	Madagascar	TT	Trinidad and Tobago
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain	MN	Mongolia	US	United States of America
FI	Finland			UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

RAPAMYCIN CONJUGATES AND ANTIBODIES

BACKGROUND OF THE INVENTION

5

This invention relates to derivatives of rapamycin which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin or ring opened derivatives thereof, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof.

10

Rapamycin is a macrocyclic triene antibiotic produced by Streptomyces hygroscopicus, which was found to have antifungal activity, particularly against Candida albicans, both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721 (1975); S.N. Sehgal et al., J. Antibiot. 28, 727 (1975); H. A. Baker et al., J. Antibiot. 31, 539 (1978); U.S. Patent 3,929,992; and U.S. Patent 3,993,749].

15

Rapamycin alone (U.S. Patent 4,885,171) or in combination with picibanil (U.S. Patent 4,401,653) has been shown to have antitumor activity. R. Martel et al. [Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed that rapamycin is effective in the experimental allergic encephalomyelitis model, a model for multiple sclerosis; in the adjuvant arthritis model, a model for rheumatoid arthritis; and effectively inhibited the formation of IgE-like antibodies.

20

The immunosuppressive effects of rapamycin have been disclosed in FASEB 3, 3411 (1989). Cyclosporin A and FK-506, other macrocyclic molecules, also have been shown to be effective as immunosuppressive agents, therefore useful in preventing transplant rejection [FASEB 3, 3411 (1989); FASEB 3, 5256 (1989); R. Y. Calne et al., Lancet 1183 (1978); and U.S. Patent 5,100,899].

25

Rapamycin has also been shown to be useful in preventing or treating systemic lupus erythematosus [U.S. Patent 5,078,999], pulmonary inflammation [U.S. Patent 5,080,899], insulin dependent diabetes mellitus [Fifth Int. Conf. Inflamm. Res. Assoc. 121 (Abstract), (1990)], adult T-cell leukemia/lymphoma [European Patent Application 525,960 A1], and smooth muscle cell proliferation and intimal thickening following vascular injury [Morris, R. J. Heart Lung Transplant 11 (pt. 2): 197 (1992)].

30


Mono- and diacylated derivatives of rapamycin (esterified at the 28 and 43 positions) have been shown to be useful as antifungal agents (U.S. Patent 4,316,885) and used to make water soluble prodrugs of rapamycin (U.S. Patent 4,650,803). Recently, the numbering convention for rapamycin has been changed; therefore
5 according to Chemical Abstracts nomenclature, the esters described above would be at the 31- and 42- positions. U.S. Patent 5,100,883 discloses fluorinated esters of rapamycin. U.S. Patent 5,118,677 discloses amide esters of rapamycin. U.S. Patent 5,118,678 discloses carbamates of rapamycin. U.S. Patent 5,130,307 discloses aminoesters of rapamycin. U.S. Patent 5,177,203 discloses sulfonates and sulfamates
10 of rapamycin. U.S. Patent 5,194,447 discloses sulfonylcarbamates of rapamycin. PCT Publication WO 92/05179 discloses carboxylic acid esters of rapamycin.

Yatscoff has reported that rapamycin levels can be quantitated using HPLC method with a sensitivity of 1 ng/ml [Ther. Drug Monitoring 14: 138 (1992)] This method is time consuming and each sample must be assayed individually.

15 Immunoassays have been developed for numerous proteins as well as various drugs including cyclosporin A [Morris, R.G., Ther. Drug Monitoring 14: 226- (1992)], and FK506 [Tamura, Transplant Proc. 19: 23 (1987); Cadoff, Transplant Proc. 22: 50 (1990)]. Numerous types of immunoassays, that have been developed to measure proteins or compounds, have been based on competitive inhibition, dual
20 antibodies, receptor-antibody interactions, antigen capture, dipstick, antibody or receptor trapping, or on affinity chromatography. Affinity columns with rapamycin have been reported in which a rapamycin analog was covalently attached to a matrix [Fretz J. Am. Chem. Soc. 113: 1409 (1991)]. These columns have been used to isolate rapamycin binding proteins.

25 DESCRIPTION OF THE INVENTION

This invention provides a rapamycin conjugate of formula I, having the structure



wherein R^1 and R^2 are each, independently, hydrogen or $-(R^3-L-R^4)_a$;

L is a linking group;

R^3 is selected from the group consisting of carbonyl, $-S(O)-$, $-S(O)_2$, $-P(O)_2-$,
 5 $-P(O)(CH_3)-$, $-C(S)-$, and $-CH_2C(O)-$;

R^4 is selected from the group consisting of carbonyl, $-NH-$, $-S-$, $-CH_2-$, and $-O-$;

$a = 1 - 5$;

$x = 0 - 1$;

$y = 0 - 1$;


10 z is from about 1 to about 120;

and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix,
 or a salt thereof with the proviso that R^1 and R^2 are both not hydrogen; and
 further provided that when a is greater than 1, each L group can be the same or
 different; and still further provided that x is 0 if R^1 is hydrogen and y is 0 if R^2
 15 is hydrogen, and if x and y are both 1, the Carrier moiety is the same in both
 cases.

The linking group, L , is any moiety that contains the group R^3 on one end and
 R^4 on other end, therefore enabling the linking group to be connected to the 42- and/or
 20 31-hydroxyl groups of rapamycin on one end and connected to another linking group
 or the immunogenic carrier material, detector material, or matrix on the other end.
 When a is greater than 1, each L group can be the same or different. In such cases, the
 first L group is designated as L^1 , the second L group designated as L^2 and so on. The

rapamycin conjugates of the present invention may be prepared in such ways as to encompass a wide range of linking groups (L) and terminal functional groups R⁴. For example, L may be linear or branched alkylenes comprising from 1 to as many as 15, more usually 10 or less, and normally less than 6 carbon atoms (i.e., methylene, ethylene, n-propylene, iso-propylene, n-butylene, and so forth). In addition, such alkylenes can contain other substituent groups such as cyano, amino (including substituted amino), acylamino, halogen, thiol, hydroxyl, carbonyl groups, carboxyl (including substituted carboxyls such as esters, amides, and substituted amides). The linking group L can also contain or consist of substituted or unsubstituted aryl, aralkyl, or heteroaryl groups (e.g., phenylene, phenethylene, and so forth). Additionally, such linkages can contain one or more heteroatoms selected from nitrogen, sulfur and oxygen in the form of ether, ester, amido, amino, thio ether, amidino, sulfone, or sulfoxide. Also, such linkages can include unsaturated groupings such as olefinic or acetylenic bonds, disulfide, imino, or oximino groups. Preferably L will be a chain, usually aliphatic comprising between 1 and about 20 atoms, more usually between 1 and 10, excluding hydrogen, of which between 0 and 5 are heteroatoms preferably selected from nitrogen, oxygen, and sulfur. Therefore, the choice of linking group L is not critical to the present invention and may be selected by one of ordinary skill taking normal precautions to assure that stable compounds are produced.

A preferred embodiment of this invention provides a conjugate of formula II, having the structure



R^1 and R^2 are each, independently, hydrogen or $-R^3-L-R^4-$;

L is $-A-(CR^5R^6)_b[B-(CR^7R^8)_d]_e-$

A is $-CH_2-$ or $-NR^9-$;

5 B is $-O-$, $-NR^9-$, $-S-$, $-S(O)-$, or $-S(O)_2-$;

R^3 is selected from the group consisting of carbonyl, $-S(O)-$, $-S(O)_2$, $-P(O)_2-$, $-P(O)(CH_3)-$, $-C(S)-$, and $-CH_2C(O)-$;

R^4 is selected from the group consisting of carbonyl, $-NH-$, $-S-$, $-CH_2-$, and $-O-$;

10 R^5 , R^6 , R^7 , and R^8 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halo, hydroxy, trifluoromethyl, arylalkyl of 7-10 carbon atoms, aminoalkyl of 1-6 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, alkoxy of 1-6 carbon atoms, carbalkoxy of 2-7 carbon atoms, cyano, amino, $-CO_2H$, or phenyl which is
15 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or $-CO_2H$;

R^9 is hydrogen, alkyl of 1-6 carbon atoms, or aralkyl of 7-10 carbon atoms;

b = 0-10;

d = 0-10;

20 e = 0-2;


x = 0 - 1;

y = 0 - 1;

z is from about 1 to about 120;

and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix,
25 or a salt thereof with the proviso that R^1 and R^2 are both not hydrogen; and further provided that when b is greater than 1, each of the CR^5R^6 groups can be the same or different, and when d is greater than 1, each of the CR^7R^8 groups can be the same or different; and still further provided that x is 0 if R^1 is hydrogen and y is 0 if R^2 is hydrogen, and if x and y are both 1, the Carrier
30 moiety is the same in both cases.

A second preferred embodiment of this invention provides a conjugate of formula III, having the structure




R^1 and R^2 are each, independently, hydrogen or $-(R^3-L^1-R^4)_f(R^{10}-L^2-R^{11})_g\text{-Carrier}$;

L^1 is $-(CH_2)_h\text{-CHR}^{12}\text{-(CH}_2)_j\text{-}$;

5 L^2 is $-(CH_2)_k\text{-D-(CH}_2)_m\text{-E-}$;

D is $-\text{CH}_2\text{-}$, $-\text{S-S-}$, or



E is $-\text{CH}_2\text{-}$ or $-\text{C}(=\text{O})\text{NH}_2^+\text{Cl}^-$;

R^3 and R^{10} are each, independently, selected from the group consisting of carbonyl, $-\text{S(O)-}$, $-\text{S(O)}_2\text{-}$, $-\text{P(O)}_2\text{-}$, $-\text{P(O)(CH}_3\text{)-}$, $-\text{C(S)-}$, and $-\text{CH}_2\text{C(O)-}$;

10 R^4 and R^{11} are each, independently, selected from the group consisting of carbonyl, $-\text{NH-}$, $-\text{S-}$, $-\text{CH}_2\text{-}$, and $-\text{O-}$;

15 R^{12} is hydrogen, alkyl of 1-6 carbon atoms, arylalkyl of 7-10 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, $-(\text{CH}_2)_n\text{CO}_2\text{R}^{13}$, $-(\text{CH}_2)_p\text{NR}^{14}\text{R}^{15}$, carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanyalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazoymethyl, halo, trifluoromethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy,

cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or -CO₂H;

R¹⁴, and R¹⁵ are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or arylalkyl of 7-10 carbon atoms;

- 5 R¹³ is hydrogen, alkyl of 1-6 carbon atoms, arylalkyl of 7-10 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or -CO₂H;

10 f = 0-3;

g = 0-1;

h = 0-10;

j = 0-10;

k = 0-10;

15 m = 0-10;

n = 0-6;

p = 0-6;

x = 0 - 1;


y = 0 - 1;

20 z is from about 1 to about 120;

and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix, or a salt thereof with the proviso that R¹ and R² are both not hydrogen; and further provided that f and g are both not 0 and when f is greater than 1, each of the -(R³-L¹-R⁴)- moieties can be the same or different; and still further provided

25 that x is 0 if R¹ is hydrogen and y is 0 if R² is hydrogen, and if x and y are both 1, the Carrier moiety is the same in both cases.

This invention also provides a conjugate of formula IV, having the structure



wherein R^1 is $-\text{OCH}_2(\text{CH}_2)_q\text{R}^4-$;

R^4 is selected from the group consisting of carbonyl, $-\text{NH}-$, $-\text{S}-$, $-\text{CH}_2-$, and $-\text{O}-$;

$q = 0 - 6$;

5 z is from about 1 to about 120;

and Carrier is immunogenic carrier material, detector carrier material, or a solid matrix, or a salt thereof.

The immunogenic carrier material can be selected from any of those
 10 conventionally known. In most cases, the carrier will be a protein or polypeptide, although other materials such as carbohydrates, polysaccharides, lipopolysaccharides, nucleic acids and the like of sufficient size and immunogenicity can likewise be used. For the most part, immunogenic proteins and polypeptides will have molecular weights between 5,000 and 10,000,000, preferably greater than 15,000 and more usually
 15 greater than 40,000. Generally, proteins taken from one animal species will be immunogenic when introduced into the blood stream of another species. Particularly useful proteins are those such as albumins, globulins, enzymes, hemocyanins, glutelins or proteins having significant non-proteinaceous constituents, e.g., glycoproteins, and the like. Further reference for the state-of-the-art concerning conventional
 20 immunogenic carrier materials and techniques for coupling haptens thereto may be had to the following: Parker, Radioimmunoassay of Biologically Active Compounds, Prentice-Hall (Englewood Cliffs, N.J., USA, 1976), Butler, J. Immunol. Meth. 7:1-24 (1975) and Pharmacol. Rev. 29(2):103-163 (1978); Weinryb and Shroff, Drug Metab. Rev. 10:P271-283 (1975); Broughton and Strong, Clin. Chem. 22:726-732
 25 (1976); and Playfair et al., Br. Med. Bull. 30:24-31 (1974). Preferred immunogenic

carrier materials for use in the present invention are ovalbumin and keyhole limpet hemocyanin. Particularly preferred for use in the present invention is ovalbumin. The detector carrier material can be a rapamycin-linking moiety conjugated to an enzyme such as horseradish peroxidase, alkaline phosphatase, luciferase, a fluorescent moiety
5 such as fluorescein or fluorescein derivatives, Texas Red, or rhodamine, a chemiluminescent moiety, and the like. The solid matrix carrier material can be resin beads, an ELISA plate, glass beads as commonly used in a radioimmunoassay, plastic beads, solid matrix material typically used in a dipstick-type assay. When rapamycin is conjugated to a solid matrix, the resulting conjugate can be used in a dipstick assay, as
10 described in this disclosure, for the affinity purification of antibodies, or for isolating rapamycin binding proteins.

It should be noted that as used in the formulae above describing the specific rapamycin conjugates, z represents the number of rapamycin conjugated to the carrier material. The value z is sometimes referred to as the epitopic density of the
15 immunogen, detector, or solid matrix and in the usual situation will be on the average from about 1 to about 120 and more typically from 1 to 50. The densities, however, may vary greatly depending on the particular carrier material used.

When any of the compounds of this invention contain an aryl or arylalkyl
20 moiety, it is preferred that the aryl portion is a phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, quinoxalyl, thienyl, thionaphthyl, furyl, benzofuryl, benzodioxyl, benzoxazolyl, benzoisoxazolyl, or benzodioxolyl group that may be optionally mono-, di-, or tri- substituted with a group selected from alkyl of 1-6 carbon atoms, arylalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-
25 7 carbon atoms, trifluoromethyl, amino, dialkylamino of 1-6 carbon atoms per alkyl group, alkylthio of 1-6 carbon atoms, -SO₃H and -CO₂H. It is more preferred that the aryl moiety is a phenyl group that is optionally mono-, di-, or tri- substituted with a group selected from alkyl of 1-6 carbon atoms, arylalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms,
30 trifluoromethyl, amino, dialkylamino of 1-6 carbon atoms per alkyl group, alkylthio of 1-6 carbon atoms, -SO₃H and -CO₂H.

The salts are those derived from such inorganic cations such as sodium, potassium, and the like; organic bases such as: mono-, di-, and trialkyl amines of 1-6
35 carbon atoms, per alkyl group and mono-, di-, and trihydroxyalkyl amines of 1-6 carbon atoms per alkyl group, and the like; and organic and inorganic acids as: acetic,

lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.

The compounds of this invention can be prepared by reacting the 42- and/or 31-
5 hydroxyl groups of rapamycin with a suitable electrophilic reagent that will serve as the linker moiety. The following patents exemplify the preparation of the 42- and/or 31- derivatives of rapamycin that can be used as linking groups for the preparation of the compounds of this invention. The preparation of fluorinated esters of rapamycin is described in U.S. Patent 5,100,883. The preparation of amide esters is disclosed in
10 5,118,677. The preparation of carbamates of rapamycin is disclosed in U.S. Patent 5,118,678. The preparation of aminoesters of rapamycin is described in U.S. Patent 5,130,307. The preparation of sulfonates and sulfamates of rapamycin are described in U.S. Patent 5,177,203. The preparation of sulfonylcarbamates of rapamycin are described in U.S. Patent 5,194,447. The disclosures of the above cited U.S. Patents
15 are hereby incorporated by reference. From these patents, it can be seen that reactive electrophiles such as isocyanates, used in the preparation of carbamates, or sulfonyl chlorides, used in the preparation of sulfonates, can be reacted with the hydroxyl groups of rapamycin without the need for an activating agent. For the esterification of the rapamycin hydroxyl groups with a carboxylic acid, activation is usually required
20 through the use of a coupling reagent such as DCC, or a water soluble analog thereof, such as dimethylaminopropyl)-3-ethyl carbodiimide (DAEC). Representative examples of the preparation of rapamycin-linking group moieties are provided as examples below. The preparation of ether derivatives of rapamycin can be accomplished using the methodology disclosed in Example 18.

25 For the compounds of this invention in which the linker group is attached to the 42- or the 31,42-hydroxyls, the electrophile (or activated electrophile) is reacted with rapamycin to typically provide a mixture of the 42- and 31,42-derivatized rapamycin that can be separated by chromatography. For the compounds of this invention in which the linker group is attached to the 31-hydroxyl of rapamycin, the 42-hydroxyl
30 group must be protected with a suitable protecting group, such as with a tert-butyldimethyl silyl group. The 31-hydroxyl can then be reacted with a suitable electrophile to provide the derivatized rapamycin, followed by deprotection of the 42-hydroxyl group. The preparation of 42-O-silyl ethers of rapamycin and subsequent deprotection is described in U.S. Patent 5,120,842, which is hereby incorporated by
35 reference. Preparation of compounds containing different linkers at the 31- and 42-positions can be accomplished by first preparing the 42-derivatized compound and then using a different linker to derivatize the 31-position. The preparation of the 27-oxime

linking groups can be accomplished using the methodology disclosed in U.S. Patent 5,023,264, which is hereby incorporated by reference; and as described in Example 21.

The linker group attached to rapamycin can be coupled to a second linker group using standard methodology described in the peptide literature; typically by activating
5 the electrophilic moiety, with DCC type coupling reagent, or with N-hydroxysuccinimide, or as an activated ester or anhydride. The activated electrophilic end of one linking moiety can then be reacted with the nucleophilic end of the other linker moiety.

The coupling of the rapamycin linking group moiety to the immunogenic carrier
10 can be accomplished under standard literature conditions. In general, for reaction with a nucleophilic group on the immunogenic carrier material, an electrophilic moiety, such as a carboxylic acid, on the linking group is activated with a suitable activating agent such as N-hydroxysuccinimide, and then reacted with the nucleophilic moiety on the immunogenic carrier material. Examples 2 and 3 specifically exemplify this technique.
15 Similar methodology is employed for the coupling of a nucleophilic moiety on the linking group to an electrophilic moiety on the immunogenic carrier material. In such cases, the electrophilic moiety on the immunogenic carrier material is activated as described above, and then reacted with the nucleophilic end of the linking group.

The reagents used to prepare the compounds of the invention are commercially
20 available or can be prepared by methods that are disclosed in the literature.

This invention also covers analogous conjugates of other rapamycins such as, but not limited to, 29-demethoxyrapamycin, [U.S. Patent 4,375,464, 32-demethoxyrapamycin under C.A. nomenclature]; rapamycin derivatives in which the
25 double bonds in the 1-, 3-, and/or 5-positions have been reduced [U.S. Patent 5,023,262]; 42-oxorapamycin [U.S. Patent 5,023,262]; 27-oximes of rapamycin [U.S. Patent 5,023,264]; 27-hydrazones of rapamycin [U.S. Patent 5,120,726]; 29-desmethylrapamycin [U.S. Patent 5,093,339, 32-desmethylrapamycin under C.A. nomenclature]; 7,29-bisdesmethylrapamycin [U.S. Patent 5,093,338, 7,32-desmethylrapamycin under C.A. nomenclature]; and 15-hydroxy- and 15,27-bishydroxy- rapamycin [U.S. Patent 5,102,876]. The disclosures in the above cited U.S. Patents are hereby incorporated by reference. Also covered are conjugates of the rapamycin 1,3-Diels Alder adduct with diethyl azidodicarboxylate and rapamycin 1,3-Diels Alder adduct with phenyltriazoline dione. The preparation of these
35 compounds is described in Examples 14 and 15.

The compounds of this invention are rapamycin immunogen, detector, and matrix bound conjugates that are useful for the generation and detection of antibodies specific for rapamycin and derivatives thereof, for measuring levels of rapamycin or a derivative thereof in biological or laboratory fluids, and for isolating rapamycin binding proteins. Rapamycin derivatives as defined here are compounds containing a rapamycin nucleus, a metabolite of rapamycin, or a ring opened rapamycin (such as secorapamycin, described in U. S. Patent 5,252,579, which is hereby incorporated by reference), in which one or more of the hydroxyl groups has been esterified into a carboxylic ester, a carbamate, a sulfonate ester, an amide, or the like, or one or more of the ketones has been reduced to a hydroxyl group, or one or more of the double bonds has been reduced, or one ketones has been converted to an oxime or a hydrazone. Other rapamycin derivatives for which the compounds of this invention can be used for measuring levels of or generating antibodies to will be apparent to one skilled in the art based on this disclosure.

Antibodies specific for rapamycin or a derivative thereof using the rapamycin immunogen conjugates of this invention may be generated by standard techniques that are known in the art. Typically, a host animal is inoculated at one or more sites with the immunogen conjugate, either alone or in combination with an adjuvant. The typical host mammals include, but are not limited to, mice, goats, rabbits, guinea pigs, sheep, or horses. Subsequent injections can be made until a sufficient titer of antibodies are produced. The antibodies generated from the rapamycin immunogen conjugates of this invention can be used in numerous immunoassays, for determining rapamycin levels, in ELISAs, radioimmunoassays, in chemiluminescence immunoassays, and in fluorescent immunoassays. Although many variations of the immunoassay can be used (antigen capture, antibody capture, competitive inhibition, or two antibody immunoassay), a basic competitive inhibition immunoassay can be performed as follows: Antibody specific for the ligand is usually bound to a matrix. A solution is applied to decrease nonspecific binding of the ligand to the matrix. After rinsing the excess away, the antibody coupled matrix may be treated in some cases so it can be stored. In a competitive inhibition assay, the ligand standard curve is made and added with the rapamycin detector conjugate to compete for binding to the rapamycin-specific antibody. If necessary, the excess is removed. The detector molecule is detected by the standard methods used by one skilled in the art. Different formats can be used, which include but are not limited to, dipstick assays, FPIA, EMIT, ELISA, VISTA, RIA, and MEIA. Detector conjugates of the present invention can be prepared to use in the above assays. For example, the detector conjugates can be Carrier material with labeled fluorescent, chemiluminescent, or enzymatic moieties.

This invention also provides for the use of the rapamycin immunogen conjugates or antibodies specific for rapamycin or a derivative thereof in a test kit that can be commercially marketed. The test kit may be used for measuring levels of rapamycin in biological or laboratory fluids. Test kit components may include
5 antibodies to rapamycin or a derivative thereof, antisera, or rapamycin carrier conjugates. The conjugates or antibodies may be bound to a solid matrix, and rapamycin derivatives or antibodies may be radiolabeled if the assay so requires. Standard concentrations of rapamycin can be included so that a standard concentration curve can be generated. Suitable containers, microtiter plates, solid supports, test
10 tubes, trays, can also be included in any such kit. Many variations of reagents can be included in the kit depending on the type of assay used.

The following is illustrative of the use of a rapamycin immunogen conjugate of this invention to generate antibodies specific for rapamycin or a derivative thereof and detect
15 them using an ELISA format immunoassay. Five mice were immunized with 50 µg rapamycin 31,42-diester with glutaric acid conjugate with keyhole limpet hemocyanin in Complete Freund's Adjuvant) intrasplenically and after about one month were boosted with 50 µg of rapamycin 31,42-diester with glutaric acid conjugate with keyhole limpet hemocyanin in incomplete Freund's Adjuvant) into the footpads.
20 Microtiter plates (Immunolon I) were coated overnight with 100 µl of goat anti-mouse antibody (10 µg/ml in 10 mM potassium phosphate buffer, pH 7.2) at 4° C. The plates were flicked and blocked with 100 µl of 1% bovine sera albumin in phosphate buffered saline overnight at 4° C. After flicking and washing the plates thrice with 10 mM phosphate buffer, pH 7.05, 30 mM NaCl, 0.02% Triton X-100, and 0.004%
25 thimerosal wash buffer, 100 µl of each mouse sera diluted with phosphate buffer solution was added to a well and incubated at room temperature for overnight. After flicking and washing the plates thrice with wash buffer, rapamycin 31,42-diester with glutaric acid conjugate with horseradish peroxidase (compound of Example 10 (100 µl, 0.5 ng/ml) was added and incubated for 1 hour at room temperature in the dark. After
30 flicking and washing the plates thrice with wash buffer, tetramethyl benzidine (TMB) substrate with H₂O₂ was added and the plates were incubated covered for 30 min. at room temperature in the dark. The optical density was read on a spectrophotometer at 450 nm. As shown in Table I, five of the five mice had antibodies reactive for rapamycin 31,42-diester with glutaric acid conjugate with horseradish peroxidase
35 (compound of Example 10).

TABLE I

MOUSE #	DILUTION ^a	O.D.
6902	1/300	0.199
6903	1/100	0.231
6904	1/500	0.412
6905	1/100	0.121
6906	1/300	0.321
background	--	0.076

^a Dilution of mouse sera in PBS

- 5 The results in Table 1 show that mouse 6904 produced the most antibodies to the compound of Example 10. Hybridomas were generated using standard methodology. Following a splenectomy of a mouse immunized and boosted 3 times with the compound of Example 4, spleen cells were fused to SP20 cells to produce hybridomas. The hybridomas were evaluated for the production of antibodies specific for rapamycin
- 10 or a derivative thereof using an ELISA assay as briefly described below.

- 15 Microtiter plates (Immunolon I) were coated overnight with 100 μ l of goat anti-mouse antibody (10 μ g/ml in 10mM potassium phosphate buffer, pH 7.2) at 4° C. The plates were flicked and blocked with 100 μ l of 1% bovine sera albumin in phosphate buffered saline (PBS) overnight at 4° C. After flicking and washing the plates thrice with 0.2x PBS containing 0.02% Triton X-100 and 0.004% thimerosal, 100 μ l of each hybridoma supernatant was added to a well and incubated at room temperature for overnight. After flicking and washing the plates thrice with 0.2x PBS containing 0.02% Triton X-100 and 0.004% thimerosal, the compound of Example 22 (100 μ l, 0.17 μ M) was added and incubated for 1 hour at 4° C. After flicking and washing the plates thrice with 0.2x PBS containing 0.02% Triton X-100 and 0.004% thimerosal, strepavidin or avidin conjugated to horseradish peroxidase (100 μ l, 0.2 μ g/ml) was added and incubated at room temperature for 1 hour in the dark. After flicking and washing the plates thrice with 0.2x PBS containing 0.02% Triton X-100 and 0.004% thimerosal, TMB substrate and H₂O₂ was added and the plates were incubated covered for 30 min. at room temperature in the dark. The optical density was read on a spectrophotometer at 450 nm. An optical density reading of 0.25 - 3 indicates specific antibody binding. The results in Table 2 show that the hybridoma from well P4G1 is
- 20
- 25

positive for binding to the compound of Example 22, and is therefore specific for rapamycin or a derivative thereof.

TABLE 2**Screening for Monoclonal Antibodies Specific for Rapamycin or a Derivative Thereof**

WELL	OPTICAL DENSITY
P3H4	0.120
P3H5	0.105
P4G1	1.940

The hybridoma cell line in P4G1 was cloned by limiting dilution and is designated as hybridoma cell line, RAP-42-OVAF₂#1hc-. In a Fluorescent Polarization Immunoassay (FPIA), rapamycin 42-ester with succinic acid conjugate with 5-glycinyfluoresceinamine (Example 23a) was used as a tracer at a concentration of 10nM and showed a polarization of 77mP in 100mM sodium phosphate pH 7.5. After addition of an excess of FKBP12, the polarization measured 195mP whereas the addition of excess of RAP-42-OVAF₂#1MoAb yielded 84mP. The ring opened non-enzymatically transformed product of the above tracer (secorapamycin 42-ester with succinic acid conjugate with 5-glycinyfluoresceinamine; Example 24) was isolated on TLC plate (50 chloroform : 4 methanol : 0.5 acetic acid; migrated slowest of three components).

20

The rapamycin- and securapamycin-fluorescein derivatives of Examples 23 and 24 were characterized by demonstrating their binding to FKBP12 and RAP-42-OVAF₂#1 MoAb. On addition of 0.01ug FKBP12 to 1.00mL 10nM rapamycin-fluorescein the fluorescence polarization increased from 57mP to 148mP, while the fluorescence polarization of the securapamycin-fluorescein derivative increased from 49mP only to 58mP, indicating much weaker binding of the seco derivative. On addition of 5ug/mL RAP-42-OVAF₂#1 MoAb to the rapamycin derivative the fluorescence polarization was unchanged at 58mP, while the securapamycin derivative fluorescence polarization increased from 44mP to 136mP. This shows that RAP-42-OVAF₂#1 MoAb binds specifically to the securapamycin-fluorescein derivative, but not to its rapamycin-fluorescein precursor.

30

Specificity of the two systems was also demonstrated in an assay format. To 500uL 10ug/mL RAP-42-OVAF2#1 was added rapamycin or secorapamycin to give final concentrations ranging from 0 to 100nM. Addition of 500uL 20nM secorapamycin-fluorescein resulted in a fluorescence polarization of 124mP in the absence of analyte, 120mP in the presence of 100nM rapamycin, and 74mP in the presence of 100nM secorapamycin. Secorapamycin analyte thus inhibits binding of the secorapamycin fluorescein derivative to RAP-42-OVAF2#1, while rapamycin has no effect. In the converse experiment, to 500uL 0.02ug/mL FKBP12 was added rapamycin or secorapamycin to give final concentrations ranging from 0 to 100nM. Addition of 500uL 20nM rapamycin-fluorescein resulted in a fluorescence polarization of 128mP in the absence of analyte, 61mP in the presence of 100nM rapamycin, and 122mP in the presence of 100nM secorapamycin. Here rapamycin inhibited binding while secorapamycin has no effect.

A second antibody designated 34-294-163MoAb, that is specific for rapamycin was prepared as follows. A female, 6-8 week old, RBF/DnJ mouse (Jackson Laboratories, Bar Harbor, Maine) was immunized with rapamycin conjugated at the 42 position to bovine serum albumin with a hemisuccinate linker (designated as RAPA-42-HS-BSA) which was emulsified in Freund's Adjuvant (Difco, Detroit, Michigan). The primary immunization was administered with Freund's Complete Adjuvant and subsequent boosts with Freund's Incomplete Adjuvant. The animal boosting interval for this long term immunized animal was at weeks 1, 3, 9, and 19, with the respective dosage level at 50, 25, 25, and 100 µg per animal at two subcutaneous locations each time. The animal was allowed a 14 week rest period before a 5 µg prefusion boost was administered to the spleen 3 days prior to fusion.

On the day of the fusion, the mouse was euthanized by a quick cervical dislocation and the spleen was removed. The splenocytes are washed one time in Iscove's Modified Dulbecco's Medium (IMDM) (GIBCO, Grand Island, New York) and centrifuged 1000 RPM for 10 minutes. The pelleted splenocytes are combined with SP2/0 myeloma cells (Dr. Milstein, Cambridge, United Kingdom) at a 1:1 ratio, washed in IMDM, and centrifuged. The supernatant was removed and 1 ml of 50% polyethylene glycol (PEG) (American Type Culture Collection, Rockville, Maryland) was added to the pellet for 1 minute as the pellet was gently being dispersed by tapping and swirling. Thirty mLs of IMDM was added to the mixture and centrifuged as previously described. Supernate was decanted, the pellet was resuspended in IMDM with hypoxanthine, aminopterin, thymidine (HAT) (GIBCO) and 10% Fetal Bovine Serum (FBS) (Hyclone Laboratories, Logan, Utah). To enhance fusion frequency,

0.5% Salmonella typhimurium mitogen v/v (STM; RIBI Immunochem Research, Inc., Hamilton, Montana) and 1% v/v ORIGEN (Igen, Rockville, Maryland) were added to the fusion cell suspension plated into 96-well tissue culture plates.

- The primary screening of the fusion occurred on day 10 confluent cultures. An
- 5 EIA was used to detect anti-rapamycin reactivity in the supernate samples. Microtiter wells were coated with 100 μ l of a 2 μ g/ml solution of 42-HS-BSA in phosphate buffered saline (PBS) and incubated at room temperature for 2 hours. The plates were blocked for 1 hour with 200 μ l per well of 3% bovine serum albumin (BSA) in PBS. After washing the plates 3 times with distilled water, 100 μ l of culture supernate was
- 10 added per well and incubated 30 minutes. The plates were washed 3 times and 100 μ l per well of goat anti-mouse IgG+M-HRPO conjugate (Kirkegaard Perry Laboratories, Gaithersburg, Maryland) diluted in the block solution was added to the plate for a 30 minute incubation period. The plate was washed a final time and the color development utilizes O-phenylenediamine:2HCl (OPD) (Abbott Laboratories, Abbott Park, Illinois).
- 15 The relative intensity of optical density readings identified hybrid 34-294 at least 5 times that of the negative control, normal mouse serum (NMS) (Organon Teknika-Cappel, Malvern, Pennsylvania) and the hybrid was selected as a candidate for cloning and further evaluation.

- Hybrid #34-294 was cloned by limiting dilutions from 1-100 to 1-100,000.
- 20 The cloning media used was IMDM with 10% v/v FBS and 1% v/v HT Supplement (GIBCO). A 200 μ l cell suspension was added to each 96 well in the tissue culture plate.

- Clone #34-294-163 (designated as 34-294-163hc) was selected for further evaluation based on additional EIA screening of the clone supernate of confluent
- 25 cultures. The EIA screening protocol used was described previously.

- The Isotype of the monoclonal antibody secreted from the cell lines identified as 34-294-163 (designated as 34-294-163MoAb) was determined on a Mouse monoclonal antibody isotyping kit, RPN 29, (Amersham Life Science, Arlington Heights, 11). The assay was performed according to the vendor recommendations and the results
- 30 indicate an isotype of IgG1, kappa light chain.

The compounds of Examples 12 and 13 can be used in an assay for the detection of polyclonal antibodies and monoclonal antibodies specific for rapamycin or a derivative thereof as described below.

- 35 Microtiter plates (Immunolon I) were coated overnight with 100 μ l of goat anti-mouse antibody (10 μ g/ml in 10mM potassium phosphate buffer, pH 7.2) at 4° C. The plates were flicked and blocked with 100 μ l of 1% bovine sera albumin in phosphate

buffered saline overnight at 4° C. After flicking and washing the plates thrice with wash buffer, 100 µl of rabbit sera diluted 1:5 in phosphate buffered saline was added to a well and incubated at room temperature for overnight. After flicking and washing the plates thrice with wash buffer, rapamycin 42-ester with 3-[3-(4-imino-butylthio)succinimidyl]phenacylglycine conjugate with horseradish peroxidase (compound of Example 12) (100 µl, 0.5 ng/ml) or rapamycin 42 ester with (N-(3-carboxyphenyl)-3-thiosuccinimidyl)glycine conjugate with horseradish peroxidase (compound of Example 13) (100 µl, 0.5 ng/ml) was added and incubated for 1 hour at room temperature in the dark. After flicking and washing the plates thrice with wash buffer, TMB substrate with H₂O₂ was added and the plates were incubated covered for 30 min. at room temperature in the dark. The optical density was read on a spectrophotometer at 450 nm. The results are shown in Table III.

15

TABLE 3

Comparison of Anti-rapamycin Antibody Levels in Rabbits
Immunized with the Compound of Example 3 vs. Naive
Rabbits Using a Capture ELISA Assay

20

Rabbit No.	Prebleed Example 10	ΔA450 (3rd Bleed-Prebleed)		
		Example 10	Example 12	Example 13
81	0.119	0.713	0.217	0.114
89	0.136	0.037	0.026	0.020

25

The data in Table 3 show that the compounds of Examples 12 and 13 can be used to detect antibodies specific for rapamycin or a derivative thereof in a mammal, as seen in rabbit number 81.

30

The following is an example of the measurement of rapamycin concentrations using a competitive inhibition assay for rapamycin with an ELISA format using an antibody specific for rapamycin. Microtiter plates (Immunolon I) were coated overnight with 100 µl of goat anti-mouse antibody (10 µg/ml in 10 mM potassium phosphate buffer, pH 7.2) at 4° C. The plates were flicked and blocked with 100 µl of 1% bovine sera albumin in phosphate buffered saline overnight at 4° C. After flicking and washing the plates thrice with wash buffer, the rapamycin specific antibody described above (100 µl of 1µg/ml) was added to each well and incubated at room temperature for 1-4 hour. After flicking and washing the plates thrice with wash buffer, rapamycin 31,42-bis(hemiglutarate) conjugate with horseradish peroxidase (100

35

5 μ l, 0.5 ng/ml) was added and incubated for 1 hour at room temperature in the dark. After flicking and washing the plates thrice with wash buffer, TMB substrate was added and the plates were incubated covered for 5 min at room temperature in the dark. The optical density was read on a spectrophotometer at 450 nm. Results of the competition between rapamycin and rapamycin 31,42-diester with glutaric acid conjugate with horseradish peroxidase binding to mouse sera are shown in Table 4. From these results, a standard curve can be constructed and the concentration of rapamycin in a sample can be determined.

10

TABLE 4

Free RAPAMYCIN	OPTICAL DENSITY x1000			% Inhibition
	<u>1</u>	<u>2</u>	<u>Avg</u>	
10 μ M	158	158	158	74.1
5	182	194	188	69.2
0.5	304	322	313	48.6
0.05	494	501	498	18.4
0.005	528	546	537	11.9
0.0005	601	611	606	0.6
0	583	636	610	--

15 The compound of Example 11 (rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)carbonyl]glycine) can be deprotected by the procedure used in Example 12 (to give rapamycin 42-ester with glycine) and conjugated to a solid matrix. It can bind antibodies specific for rapamycin or a derivative thereof as used in some dipstick immunoassay methods or to isolate rapamycin binding proteins. The following
20 example illustrates that 803 resonance units (RU) of the compound of Example 11 can be immobilized on a solid matrix using the BIAcore's standard protocol based on EDC and NHS used in a BIAcore. This matrix bound 1401 RU units of rapamycin specific antibody. The kinetics of association and dissociation were determined for each concentration of antibody tested (0.625, 1.25, 2.5, 5.0, 10.0 μ g/ml). These data show
25 that the compound of Example 11, even when bound to a matrix was accessible to binding by a ring opened rapamycin-specific antibody and the interaction could be characterized. Similar procedures can be used to bind a rapamycin-binding protein to deprotected rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)carbonyl]glycine

conjugated matrix. This matrix can also be used for the isolation of novel binding proteins, as practiced by one skilled in the art. Deprotected rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)carbonyl]glycine can be used to isolate binding proteins of rapamycin-FKBP complex by one of the following methods. In one approach, tissue
5 or cell lysates containing the appropriate protease inhibitors are incubated with FKBP which has been incubated with a deprotected-rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)carbonyl]glycine conjugated matrix for a sufficient time to allow binding. Various buffers are used to rinse the proteins which are nonspecifically bound. Proteins are released by the addition of additional buffers which disrupt the bond
10 between the rapamycin nucleus-FKBP and the binding proteins.

The hybridoma cell line, RAP-42-OVAF₂#1hc, was deposited under the terms of the Budapest Treaty at the American Type Culture Collection (ATCC) of 12301 Parklawn Drive, Rockville, Maryland, 20852, USA, on March 10, 1994, and was
15 granted accession number HB 11568.

The hybridoma cell line 34-294-163hc has also been deposited under the terms of the Budapest Treaty at the ATCC on April 6, 1994, and was granted accession number HB 11606.

20 The following examples represent the preparation of representative compounds of this invention.

Example 1

Rapamycin 42-ester with succinic acid

25 1.1 g (11mmol) of succinic anhydride and 400 mg of dimethylaminopyridine (DMAP) were added to a stirring solution of 5g (5.5mmol) of rapamycin and 880 µl of pyridine in 15 ml of methylene chloride. The reaction mixture was stirred for 2 days at room temperature, diluted with methylene chloride and washed with three 50 ml portions of 1N HCl. The organic layer was then dried over Na₂SO₄ and concentrated
30 in vacuo affording crude product. Pure material was obtained by reverse phase HPLC with 55% acetonitrile/water as eluant affording 1g (18%) of the title compound. Spectral data follows: ¹H NMR (CDCl₃, 300 MHz) 4.650 (m, 1H, H₂COC=O), 4.168 (d, 1H, H₂COH), 2.795 (s, 4H, OC=OCH₂CH₂C=O).

Example 2**Rapamycin 42-ester with (N-hydroxysuccinimide(hemisuccinate))**

21 mg (0.098 mmol) of DCC and 12 mg (0.098 mmol) of N-hydroxysuccinimide were added to a stirring solution of 100 mg of rapamycin 42-ester with succinic acid in 3 ml ethyl acetate. The reaction mixture was stirred overnight at room temperature, filtered, and concentrated in vacuo affording crude product. Pure material was obtained by reverse phase HPLC with 80% acetonitrile/water as eluant affording 75 mg (69%) of the title compound. Spectral data follows: ¹H NMR (CDCl₃, 300 MHz) 4.650 (m, 1H, H₂COC=O), 4.168 (d, 1H, H₂COH), 2.951 (m, 2H, OC=OCH₂), 2.795 (m, 4H, OC=OCH₂CH₂C=O), 2.705 (m, 2H, OC=OCH₂); MS (neg.ion FAB) 1110 (M⁻), 1056, 1012, 913, 148 (100).

Example 3**Rapamycin 42-ester with succinic acid conjugate with keyhole limpet hemocyanin**

197 mg of keyhole limpet hemocyanin in 6 ml of 0.05 M phosphate buffer was added to a stirring solution of 37 mg of rapamycin 42-ester with (N-hydroxysuccinimide(hemisuccinate)) in 3 ml of 1,4 dioxane and the reaction was left stirring for 3 days at 4°C. The reaction mixture was then dialyzed for 24 hr at 4°C in 1500 ml of 0.05 M phosphate buffer to give the title compound which could be used without further purification. The number of rapamycin 42-ester with succinic acid moieties per keyhole limpet hemocyanin was approximately 42:1.

Example 4**Rapamycin 42-ester with succinic acid conjugate with ovalbumin**

197 mg of ovalbumin in 6 ml of 0.05 M phosphate buffer was added to a stirring solution of 37 mg of rapamycin 42-ester with (N-hydroxysuccinimide(hemisuccinate)) in 3 ml of 1,4 dioxane and the reaction was left stirring for 3 days at 4°C. The reaction mixture was then dialyzed for 24 hr at 4°C in 1500 ml of 0.05 M phosphate buffer to give the title compound which could be used without further purification.

Example 5**Rapamycin 42-ester with succinic acid conjugate with horseradish peroxidase**

16 mg of horseradish peroxidase in a solution of 0.4 ml of 1,4 dioxane and 0.4 ml of 0.5% sodium bicarbonate was added to 1 mg of rapamycin 42-ester with (N-

hydroxysuccinimide(hemisuccinate)) in 40 μ l of 1,4 dioxane and the reaction left stir for 2.5 hr at 4°C. The reaction mixture was then dialyzed for 24 hr at 4°C in 1500 ml of 0.05 M phosphate buffer to give the title compound which could be used without further purification.

5

Example 6

Rapamycin 31,42-diester with glutaric acid

The title compound was prepared according to the method used in Example 1.

10

Example 7

Rapamycin 31,42-diester with (N-hydroxysuccinimide(hemiglutarate))

To a solution of 15.9 mg of rapamycin 31,42-diester with glutaric acid in 160 μ L of dimethyl formamide was added 3.65 mg of N,N-dimethylaminopropyl-ethylcarbodiimide and 1.8 mg of N-hydroxysuccinimide. The reaction mixture was allowed to stir until reaction was complete, poured into water, and extracted with ethyl acetate. The organic layers were combined, dried over sodium sulfate, filtered, and concentrated in vacuo to give the title compound, which was stored at 4°C at 0.1 N sodium phosphate buffer and used without further purification.

20

Example 8

Rapamycin 31,42-diester with glutaric acid conjugate with keyhole limpet hemocyanin

To 20 mg of keyhole limpet hemocyanin in 2 mL of 0.1 M NaHCO₃ was added 55 μ L of rapamycin 31,42-diester with (N-hydroxysuccinimide(hemiglutarate)) at 0°C in 10 μ L increments over a 30 min period. The solution was gently shaken until reaction was complete, centrifuged at 6000 rpm for 20 min, and unconjugated starting material was separated from the title compound on a G-25 column with phosphate buffer solution. The conjugate was mixed with glycerol at 50% and stored at -70°C. The number of rapamycin 31,42-diester with glutaric acid moieties per keyhole limpet hemocyanin ranged from 17-45:1.

30

Example 9

Rapamycin 31,42-diester with glutaric acid conjugate with ovalbumin

To 20 mg of ovalbumin in 2 mL of 0.1 M NaHCO₃ was added 55 μ L of rapamycin 31,42-diester with (N-hydroxysuccinimide(hemiglutarate)) at 0°C in 10 μ L increments over a 30 min period. The solution was gently shaken until reaction was complete, centrifuged at 6000 rpm for 20 min, and unconjugated starting material was

35

separated from the title compound on a G-25 column with phosphate buffer solution. The conjugate was mixed with glycerol at 50% and stored at -70°C.

Example 10

5 Rapamycin 31,42-diester with glutaric acid conjugate with horseradish peroxidase

To 10 mg of horseradish peroxidase in 1 mL of 0.1 M NaHCO₃ was added 105 µL of rapamycin 31,42-diester with (N-hydroxysuccinimide(hemiglutarate)) in 10 µL increments over a 30 min period. The solution was gently shaken until complete,
10 centrifuged at 6000 rpm for 20 min, and eluted from a G-25 column with phosphate buffer solution. The conjugate was mixed with glycerol at 50% and stored at -20°C.

Example 11

Rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)carbonyl]glycine

15 To a chilled (0°C) solution of rapamycin (0.73 g, 0.08 mmol) in methylene chloride (5 mL) was added 0.6 g (1.19 mmol) of N-[(9H-fluoren-9-ylmethoxy)carbonyl]glycine pentafluorophenyl ester, followed by pyridine (0.85 mL, 10.5 mmol) and dimethylaminopyridine (18 mg, 0.14 mmol) to form a heterogeneous solution, which became homogeneous upon warming to room temperature. The
20 reaction mixture was stirred at room temperature overnight. A large excess of EtOAc was added. The organic layer was washed with 0.5 N HCl (2x) and brine, dried (MgSO₄), and concentrated to yield an off-white foam. Flash chromatography (30-50% hexane/EtOAc) yielded the title compound in 71% yield (0.679 g, 0.57 mmol). Mass spec (negative ion FAB) M⁻ at m/z 1192.

25

Example 12

Rapamycin 42-ester with 3-[3-(4-iminobutylthio)succinimidyl]phenacyl-glycine conjugate with horseradish peroxidase

To a solution of rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)-carbonyl]glycine (10 mg, 8.4 µmol) in acetonitrile (84 µL) was added 10 µL (in
30 acetonitrile at 0.84 M) of diethylamine. The reaction mixture was stirred at room temperature for 60 minutes and the solvent was removed with a stream of nitrogen. The residue was dissolved in acetonitrile (100 µL) and washed with hexane (5 times, 200 µL), followed by concentration of the solvent with a nitrogen stream. The
35 resulting rapamycin 42-ester with glycine was taken up in a solution of m-maleimidobenzoyl-N-hydroxysuccinimide (MBS) (2 mg) in DMF (200 µL) and allowed to incubate for two hours at 4°C, followed by the addition of 50 nM

ethanolamine (20 μ L) in 50 mM Tris HCl, pH 8.0. Horseradish peroxidase (5 mg) and Rabbit IgG (10 mg) were treated with 2-iminothiolane and purified with Sephadex G-25, followed by the addition of the MBS-rapamycin glycine ester adduct. The mixture was incubated overnight at 4°C and purified by gel filtration on Sephadex G-25 to provide the title compound.

Example 13

Rapamycin 42 ester with (N-(3-carboxyphenyl)-3-thiosuccinimidyl)-glycine conjugate with horseradish peroxidase

To a solution of rapamycin 42-ester with N-[9H-fluoren-9-ylmethoxy)-carbonyl]glycine (10 mg, 8.4 μ mol) in acetonitrile (84 μ L) was added 10 μ L (in acetonitrile at 0.84 M) of diethylamine. The reaction mixture was stirred at room temperature for 60 minutes and the solvent was removed with a stream of nitrogen. The residue was dissolved in acetonitrile (100 μ L) and washed with hexane (5 times, 200 μ L), followed by concentration of the solvent with a nitrogen stream. The resulting rapamycin 42-ester with glycine was taken up in a solution of N-succinimidyl S-acetylthioacetate (2 mg) in DMF (200 μ L). The reaction mixture was stirred at room temperature for 15 minutes and then at 4°C overnight. A solution of hydroxylamine HCl (7 mg in 50 μ L DMF) was added to the solution of rapamycin reaction mixture, incubated for one hour, followed by the addition of MBS-horseradish peroxidase adduct and MBS-Rabbit IgG to give the title compound which was purified by Sephadex G-25 gel filtration.

Example 14

Rapamycin 1.3. Diels Alder adduct with diethyl azidodicarboxylate

Rapamycin (1g, 1.093 mmol) and diethyl azodicarboxylate (0.381 g, 2.187 mmol) were dissolved in dichloromethane (10 ml) and heated at 65°C overnight, TLC showed that the reaction was complete. The mixture was purified on a silica gel column using ethyl acetate as eluant to provide a white solid (0.750 g) which was triturated with hexane and air dried to give the title compound (0.666 g) as a powder. Anal Calc for C₅₇H₈₉N₃O₁₇: C, 62.91; H, 8.24; N, 3.86. Found: C, 62.81; H, 8.12; N, 3.91
IR (KBr, cm⁻¹) 3450, 1720
NMR (CDCl₃) δ 6.15 (m, 1H), 5.20 (d, 1H), 3.40 (s, 3H), 3.30 (s, 3H), 3.15 (s, 3H), 0.9 (t, 3H), 0.72 (q, 1H)
MS (-FAB) 1087 (M⁻)

Example 15**Rapamycin 1.3. Diels Alder adduct with Phenyltriazolinedione**

Rapamycin (0.66g, 721 μmol) was dissolved in dichloromethane (10 ml) and cooled to 0°C. To this was added, dropwise, a solution of phenyltriazolinedione (0.133 g, 758 μmol) in dichloromethane (10 ml). The solution was stirred overnight, TLC showed the reaction was not complete. Additional phenyltriazolinedione (0.025g, 27 μmol) was added. The reaction was purified using HPLC (4.1x31cm, SiO₂) with ethyl acetate as eluant to provide the title compound as a solid. The solid was triturated with 30 ml of hexane and 1 ml of ethyl acetate filtered and air dried to give the title compound as a powder (0.383 g).

Anal Calc for C₅₉H₈₄N₄O₁₅: C, 65.05; H, 7.77; N, 5.14. Found: C, 65.39; H, 7.98; N, 4.92

IR (KBr, cm⁻¹) 3450, 1715

NMR (DMSO) δ 7.50 (m, 3H), 7.40 (m, 2H), 3.11 (s, 3H), 3.00 (s, 3H) 2.95 (s, 3H), 0.8 (q, 1H)

MS (-FAB) 1088 (M⁻)

The following are representative examples of fluorescent rapamycin derivatives that can be conjugated via a linker at the 31-position of rapamycin.

Example 16**42-Dansylrapamycin**

Rapamycin (200 mg, 0.22 μmol) in dry pyridine (2 ml) was cooled to 0°C and was treated with dansyl chloride (840 mg, 3.1 μmol). The reaction was warmed to room temperature and stirred for 24 hours. The reaction mixture was poured into cold 2N HCl (30 ml) and was extracted with ethyl acetate (4x25 ml). The ethyl acetate was pooled and washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was chromatographed on silica with 25% ethyl acetate in benzene. This afforded 150 mg of the title compound as a yellow powder, mp 101-104°C.

Example 17**Rapamycin 42-ester with pyrene butyric acid**

Rapamycin (459 mg, 0.5 μmol) and pyrenebutyric acid (216 mg, 0.75 μmol) were dissolved in THF/CH₂Cl₂ (10 ml, 1:1). 1-(3-Dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (146 mg, 0.67 μmol) and 4-dimethylaminopyridine (15 mg) were added to the solution. The reaction was allowed to warm to room temperature over 15 hours. The reaction was diluted with CH₂Cl₂ and washed with

5% HCl, then brine. The solution was dried over MgSO₄, filtered and evaporated to a solid. The solid was applied to a 3 mm silica gel Chromatron plate which was eluted with 50% ethyl acetate in hexane to provide 180 mg of the title compound as a foam. The reaction also afforded 100 mg of 31,42-diesterified rapamycin.

5 IR (KBr, cm⁻¹) 3420, 1740

NMR (CDCl₃) δ 8.3 (d, 1H), 8.14 (dd, 2H), 8.10 (d, 2H), 7.85 (d, 1H), 3.34 (s, 3H), 3.30 (s, 3H), 3.11 (s, 3H)

MS (-FAB) 1183 (M⁻)

10 The following are representative examples of rapamycin derivatives that can be conjugated to immunogenic carriers by the procedures described above or can be connected to another linker and then conjugated.

Example 18

15 **Rapamycin 42-carbomethoxymethyl ether and Rapamycin 42-bis(carbomethoxymethyl ether)**

Rapamycin (2.0 g, 2.187 mmol) and rhodium (II) acetate (0.37 g, 0.08 mmol) were heated to reflux in benzene and treated with a solution ethyl diazoacetate (500 ml) in benzene (10 ml) over 10 minutes. The solution was cooled to room temperature and
20 was stirred overnight. TLC showed that the reaction was incomplete. Two additional portions of ethyldiazoacetate (3 ml) were added at 24 hour intervals. The mixture was concentrated and purified by flash chromatography over silica using ethyl acetate. This provided the 42-monoether (1 g) and the 31,42 diether (0.850 g) as oils. The 42-monoether was triturated in a mixture of hexane, ethyl acetate and dichloromethane over
25 the weekend to give the product as a powder. The diether was purified on HPLC on a silica gel column with ethyl acetate as eluant. This provided the product as a solid.

Analytical data for the monoether:

Analysis Calc for C₅₅H₈₅NO₁₅: C, 66.04; H, 8.57; N, 1.40. Found: C, 65.29; H, 8.64; N, 1.60

30 IR (KBr, cm⁻¹) 3420, 1715

NMR (CDCl₃) δ 4.82 (s, 1H), 3.41 (s, 3H), 3.33 (s, 3H), 3.13 (s, 3H), 1.28 (t, 3H), 0.70 (q, 1H)

MS (-FAB) 999 (M⁻)

Analytical data for the diether:

35 Analysis Calc for C₅₉H₉₁NO₁₇: C, 65.23; H, 8.44; N, 1.29. Found: C, 63.29; H, 8.40; N, 1.44

IR (KBr, cm⁻¹) 1740

NMR (CDCl₃) δ 6.36 (q, 2H), 5.24 (s, 1H), 3.39 (s, 3H), 3.32 (s, 3H), 3.12 (s, 3H), 0.65 (q, 1H)

MS (-FAB) 1085 (M⁻)

5

Example 19

Rapamycin 42-(4-nitrophenyl)carbonate and Rapamycin 31,42-bis(4-nitrophenyl)carbonate

Rapamycin (0.450 g, 0.49 mmol) was dissolved in dry dichloromethane (10 ml) and cooled to 0°C. To this solution was added pyridine (0.4 ml, 5.7 mmol) and a crystal of 4-dimethyl aminopyridine. A solution of 4-nitrophenyl chloroformate (0.3 g 1.49 mmol) in dichloromethane (3 ml) was added. The solution was allowed to warm to room temperature overnight and was stirred at room temperature for 24 hours. The reaction was quenched into 0.1N HCl (5 ml) and the aqueous layer was washed with dichloromethane. The organic layer was dried over MgSO₄, filtered, and evaporated in vacuo to afford a yellow solid. Chromatography over silica gel with 75% Ethyl acetate in hexane afforded 180 mg of the 42-monocarbonate and 47 mg of the 31,42-dicarbonate as yellow solids.

20

Example 20

42-O-(Phenoxythiocarbonyl)-rapamycin

Rapamycin (1.030 g, 1.12 mmol) was dissolved in dry dichloromethane (100 ml) and was cooled to 0°C. To this solution was added pyridine (0.27 ml, 3.33 mmol) and a crystal of 4-dimethyl aminopyridine. A solution of thiophenyl chloroformate (0.47 ml 1.49 mmol) in dichloromethane (5 ml) was added to the reaction mixture. The solution was allowed to warm to room temperature overnight and was stirred at room temperature for 24 hours. The reaction was quenched into 0.1N HCl (5 ml) and the aqueous layer was washed with dichloromethane. The organic layer was dried over MgSO₄, filtered and evaporated in vacuo to afford a yellow solid. Chromatography on a 4 mm silica gel Chromatotron plate with a gradient of 40% to 70% ethyl acetate in hexane afforded 520 mg of the title compound as a yellow foam.

Analysis Calc for C₅₈H₈₃NOS₁₄: C, 66.32; H, 7.97; N, 1.33. Found: C, 66.48; H, 8.05; N, 1.12

IR (KBr, cm⁻¹) 3420, 1715

NMR (CDCl₃) δ 7.41 (t, 1H), 7.25 (t, 2H), 7.12 (d, 1H), 3.45 (s, 3H), 3.33 (s, 3H), 3.13 (s, 3H)

MS (-FAB) 1049 (M⁻)

35

Example 21**Rapamycin-O-carboxymethyl-27-oxime**

To a solution of 600 mg (650 μ M) of rapamycin in 6 mL of methanol was added at room temperature, 100 mg (1.2 mmol) of anhydrous sodium acetate and 140 mg (660 μ M) of carboxymethoxylamine hemihydrochloride. After stirring overnight at room temperature, the reaction was complete. The reaction mixture was concentrated in vacuo and the residue was triturated with water. The solids were filtered and washed thoroughly with water. The product was dried under high vacuum to give 575 mg (89.7%) of a white solid. ^{13}C and ^1H NMR indicated a mixture of E and Z isomers for the oxime derivative at position 27.

^1H NMR (CDCl_3 , 400 MHz): 3.43 and 3.41 (2s, 3H, CH_3O), 3.30 (s, 3H, CH_3O), 3.18 and 3.12 (2s, 3H, CH_3O), 1.82 (s, 3H, $\text{CH}_3\text{C}=\text{C}$), 1.695 and 1.633 (2s, 3H, $\text{CH}_3\text{C}=\text{C}$); ^{13}C NMR (CDCl_3 , MHz): 215.8 (C=O), 211.5 (C=O), 194.5 (C=O), 191.0 (C=O), 172.5 (C=O), 169.0 (C=O), 168.5 (C=O), 167.0 (C=O), 161.5 (C=NOC), 160.0 (C=NOC), 140.0; MS (neg. ion FAB: 985 (M-H) $^-$, 590, 167, 128, 97, 75 (100%)

Analysis Calcd for $\text{C}_{53}\text{H}_{82}\text{N}_2\text{O}_{15} \cdot 0.15 \text{H}_2\text{O}$: C 63.90; H 8.40; N 2.81

Found : C 63.81; H 8.41; N 2.85

The following compound was used in the generation of antibodies specific for rapamycin or a derivative thereof.

Example 22**Rapamycin 42-ester with glycylobiotin**

To a solution of biotin (0.83 g, 3.4 mmol) in 60 mL of DMF was added glycine t-butyl ester hydrochloride (0.57 g, 3.4 mmol), N-methylmorpholine (0.92 mL, 8.36 mmol), 1-hydroxybenzotriazole (0.61 g, 3.99 mmol) and 1-(3-Dimethylaminopropyl)-3-ethylcarbo-diimide hydrochloride (0.65 g, 3.4 mmol). The reaction mixture was stirred at room temperature for 7 days. The DMF was concentrated, ethyl acetate was added, and the organic layer was washed with water, 0.5 N HCl, saturated sodium bicarbonate, and brine. The ethyl acetate layer was dried (MgSO_4) and concentrated to yield tert-butylglycylobiotin as a white solid which was primarily one spot on TLC (0.611 g, 1.71 mmol, 50%). Mass spec $[\text{M}+\text{H}]^+$ at m/z 358.

To a solution of tert-butylglycylobiotin (0.271 g, 0.758 mmol) in CH_2Cl_2 (0.5 mL) was added 0.5 mL trifluoroacetic acid. The reaction mixture was stirred at

room temperature for 2h, concentrated, and triturated with anhydrous diethyl ether. The off-white precipitate was collected to yield 0.209 g (0.694 mmol, 92%) of glycylobiotin. Mass spec $[M+H]^+$ at m/z 302.

To a solution of glycylobiotin (0.65 g, 2.16 mmol) in 1-methylpyrrolidinone
5 (5 mL) was added 6 mL of CH_2Cl_2 , causing a precipitate to form which persisted even after the addition of 0.33 mL (2.36 mmol) of triethylamine. To this heterogeneous solution was added 2 g (2.19 mmol) of rapamycin, 0.43 g (2.24 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and 30 mg (2.46 mmol) of DMAP. After several hours, the reaction mixture became homogenous, and was stirred
10 an additional four days. A large excess of ethyl acetate was added and the organic layer was washed with water, 0.5 N HCl, saturated sodium bicarbonate, and brine. The organic layer was dried ($MgSO_4$) and concentrated. The light yellow foam was triturated with hot anhydrous diethyl ether to yield 1.2 g of impure title compound as a light yellow solid. A portion (0.5 g) of this material was flash chromatographed in 5%
15 MeOH/ $CHCl_3$, and triturated again in hot ether to yield 87 mg of the title compound contaminated with a small amount of rapamycin. This material was rechromatographed (gradient 0-5% MeOH/ $CHCl_3$), and triturated a final time with ether to yield 34 mg (0.028 mmol) of pure title compound as a white solid. Mass spec, negative FAB M^- at m/z 1196.

20

Example 23

a) Rapamycin-42-ester with succinic acid conjugate with 5-glycinyfluoresceinamine

To 4.2mg 5-glycinyfluoresceinamine dissolved in 200uL methanol containing
25 10uL triethylamine was added 4mg of the compound of Example 2. After 2 hours a portion of the mixture was applied to a silica thin layer chromatography plate and developed with 100 parts chloroform, 10 parts methanol, 1 part acetic acid. After drying, the band containing product was scraped from the plate, and the product eluted from the silica with methanol. The product was characterized by the change in
30 fluorescence polarization of aqueous solution on addition of FKBP12.

b) Rapamycin 42-ester with succinic acid conjugate with 5-aminomethylfluorescein

By following the method of Example 23a, the title compound was prepared by
35 substituting 2.5 mg 5-aminomethylfluorescein for 5-glycinyfluorescein.

c) Rapamycin 42-ester with succinic acid conjugate with 4'-aminomethylfluorescein

By following the method of Example 23a, the title compound was prepared by substituting 1.1 mg 4'-aminomethylfluorescein for 5-glycinyfluorescein. The thin layer chromatography solvent was 100 parts chloroform, 8 parts methanol, and 1 part acetic acid.

Example 24

Secorapamycin 42-ester with succinic acid conjugate with 5-glycinyfluoresceinamine

A portion of the product of Example 23 was applied to a silica thin layer chromatography plate, and eluted with a mixture of 50 parts chloroform, 4 parts methanol and 0.5 part acetic acid. Three mobile fluorescent bands were observed, with unchanged starting material having the highest rf value and the title compound having the lowest rf value. The silica containing the desired product was scraped from the plate and the title compound was eluted with methanol. The product was characterized by the change in fluorescence polarization of an aqueous solution on addition of RAP-42-OVAF2#1 MoAb.

Example 25

a) Rapamycin 42-ester with adipic acid.

Rapamycin 42-ester with adipic acid was prepared by a variation of the method of Example 2. Adipic anhydride was prepared by combining 146 mg adipic acid in 1.0 mL dimethylformamide with 200 μ L dicyclohexylcarbodiimide and incubating at room temperature 2h. 300 μ L of the supernatant of this reaction was added to 90 mg rapamycin and 45 mg dimethylaminopyridine dissolved in 200 μ L methylene chloride. After 5 min the mixture was centrifuged to sediment precipitated material. The supernatant was partitioned between 3 mL water with 100 μ L acetic acid and 2 X 1 mL methylene chloride. The organic layers were combined, dried with anhydrous sodium sulfate and the solvent evaporated. The residue was dissolved in 1.0 mL methanol and 0.5 mL ethanol, cooled in ice, and precipitated by adding 5 mL water. This was centrifuged, the supernatant discarded and the residue dried in a vacuum desiccator, yielding 78 mg white powder.

**b) Rapamycin 42-ester with adipic acid, ester with
n-hydroxysuccinimide.**

38 mg of the compound of Example 25a, 38 mg of N-hydroxysuccinimide, and 40 mg of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide were mixed with 0.4 mL dimethylformamide. After 60 min an additional 40 mg of the carbodiimide was added. After an additional 60 min the mixture was cooled in ice, and 4 mL water added while vortexing. The precipitate was collected by centrifugation, washed by resuspending and centrifuging twice with 5 mL water, and dried in a vacuum desiccator, yielding 38 mg white powder.

**c) Rapamycin 42-ester with adipic acid conjugate with
5-glycinyfluoresceinamine.**

2.3 mg 5-glycinyfluoresceinamine dissolved in 200 μ L methanol by addition of 6 μ L triethylamine. 60 μ L of a solution of 10.6 mg of the compound of Example 25b in 200 μ L methanol was added. After 25 min the mixture was applied to a silica thin layer chromatography plate and developed with a mixture of 100 parts chloroform, 12 parts methanol and 1 part acetic acid. The silica containing the desired product was scraped from the plate and the title compound eluted with methanol.

**d) Rapamycin 42-ester with adipic acid conjugate with
5-aminomethylfluorescein.**

The title compound was prepared as in Example 25c, but using 2.6 mg 5-aminomethylfluorescein.

**e) Rapamycin 42-ester with adipic acid conjugate with
4'-aminomethylfluorescein.**

The title compound was prepared as in Example 25c, but using 2.5 mg 4'-aminomethylfluorescein. The thin layer chromatography solvent was 100 parts chloroform, 4 parts methanol and 2 parts acetic acid.

CLAIMS

What is claimed is:

1. A rapamycin 42-ester with a dicarboxylic acid conjugate to a fluorescein
5 derivative.
2. The conjugate of claim 1 wherein the dicarboxylic acid is succinic acid.
3. The conjugate of claim 2 wherein the derivative of fluorescein is 5-
10 glycinyfluoresceinamine, 5-aminomethylfluorescein, or 4'-aminomethylfluorescein.
4. The conjugate of claim 1 wherein the dicarboxylic acid is adipic acid.
5. The conjugate of claim 4 wherein the derivative of fluorescein is 5-
15 glycinyfluoresceinamine, 5-aminomethylfluorescein, or 4'-aminomethylfluorescein.
6. In an immunoassay method for determining levels of rapamycin or a derivative
thereof, the improvement comprises using the conjugate of claim 1 as a detector
20 molecule.
7. A test kit for measuring levels of rapamycin or a derivative thereof comprising
the rapamycin conjugate of claim 1 and an antibody capable of specifically binding to
rapamycin or a derivative thereof.
8. A secorapamycin 42-ester with a dicarboxylic acid conjugate to a fluorescein
25 derivative.
9. The conjugate of claim 8 wherein the dicarboxylic acid is succinic acid.
10. The conjugate of claim 9 wherein the fluorescein derivative is 5-
30 glycinyfluoresceinamine.
11. In an immunoassay method for determining levels of rapamycin or a derivative
thereof, the improvement comprises using the conjugate of claim 8 as a detector
35 molecule.

12. A test kit for measuring levels of rapamycin or a derivative thereof comprising the rapamycin conjugate of claim 8 and an antibody capable of specifically binding to rapamycin or a derivative thereof.
- 5 13. A monoclonal antibody specifically binding to a ring opened rapamycin which is designated as RAP-42-OVAF₂#1MoAb.
14. The monoclonal antibody of claim 13, wherein the ring opened rapamycin is secorapamycin.
- 10 15. A test kit for determining levels of a ring opened rapamycin or a derivative thereof, the improvement comprises employing the antibody of claim 13.
16. A method of separating a mixture of a ring opened rapamycin or a derivative thereof from rapamycin or a derivative thereof, which comprises treating the mixture with the antibody of claim 13 bound to a solid matrix, and eluting the unbound rapamycin from the bound open chain rapamycin-antibody-solid matrix complex.
- 15 17. A method of separating a mixture of a ring opened rapamycin or a derivative thereof from rapamycin or a derivative thereof, which comprises treating the mixture with the antibody of claim 13, capturing the ring opened rapamycin-antibody complex with a solid support, and eluting the unbound rapamycin from the open chain rapamycin-antibody-solid matrix complex.
- 20 18. A method of separating a mixture of a ring opened rapamycin or derivative thereof from rapamycin or a derivative thereof, which comprises treating the mixture with the antibody of claim 13, followed by anti-mouse immunoglobulin, and removing the precipitated ring opened rapamycin-antibody-anti-mouse immunoglobulin complex.
- 25 19. The method according to claim 18, wherein the anti-mouse immunoglobulin is rabbit, mouse, rat, sheep, or goat antimouse immunoglobulin.
- 30 20. A method of separating a mixture of a ring opened rapamycin or a derivative thereof from rapamycin or derivative thereof, which comprises treating the mixture with the antibody of claim 13, followed by protein A or G, and removing the precipitated ring opened rapamycin-antibody-protein A or G complex.
- 35

21. A monoclonal antibody specifically binding to rapamycin which is designated as 34-294-163MoAb.
 22. A hybridoma cell line capable of producing antibodies specific for rapamycin
- 5 which is designated as 34-294-163hc.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/04434

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 31/395; G01N 33/53, 33/533, 33/536

US CL : 514/183, 291, 321; 435/7.92, 975; 436/536, 546, 808, 815

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/183, 291, 321; 435/7.92, 975; 436/536, 546, 808, 815

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO, A, 92/05179 (CAUFIELD ET AL) 02 April 1992, see the Abstract in particular.	1-7
Y	EP, A, 0,201,751(FINO ET AL) 20 November 1986, see the Abstract in particular.	1-7
Y	Linskens et al EDS., "Immunology in Plant Sciences" published 1986 by Springer-Verlag, (New York), pages 86-141, especially pages 87-92 and 94.	1-7



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z

document member of the same patent family

Date of the actual completion of the international search

28 JUNE 1994

Date of mailing of the international search report

JUL 12 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CHRISTINA CHAN

Telephone No. (703) 311-1966

INTERNATIONAL SEARCH REPORT

Int. application No.

PCT/US94/04434

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-7

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/04434

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

- I. Claims 1-7, drawn to a rapamycin 42-ester conjugate, an immunoassay and a test kit, Classes 514, 435 and 436, subclasses 183+, 7.92 and 808+, respectively.
- II. Claims 8-12, drawn to a secorapamycin 42-ester conjugate, an immunoassay and a test kit, Classes 514, 435 and 436, Subclasses 183+, 7.92 and 808+, respectively.
- III. Claims 13-16, drawn to a monoclonal antibody, a test kit and a method of separating a mixture of a ring opened rapamycin, Class, 530, Subclasses 388.9 and 413.
- IV. Claim 17, drawn to a method of separating a mixture of a ring opened rapamycin, Class 530, Subclass 413.
- V. Claims 18-19, drawn to a method of separating a mixture of a ring opened rapamycin, Class 530, Subclass 413.
- VI. Claim 20, drawn to a method of separating a mixture of a ring opened rapamycin, Class 530, Subclass 413.
- VII. Claims 21-22, drawn to a monoclonal antibody and a hybridoma, Classes 530 and 435, Subclasses 388.9 and 240.27.

The inventions as grouped are distinct, each from the other, because they represent different inventive endeavors. The conjugate, the method and the kit in Group I would not suggest the conjugate, the method and the kit in Group II. The monoclonal antibody in Group III would not suggest the monoclonal antibody in Group VII. The method of separating a mixture of a ring opened rapamycin in Group III would not suggest the method of separating a mixture of a ring opened rapamycin in Groups IV-VI. Groups I-VII are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.